The Freeze-Drying of Pharmaceuticals in Vials Nested in a Rack System-Part II: Primary Drying Behaviour.
freeze-drying
heat transfer
mannitol
primary drying
rack system
sublimation flux
sucrose
Journal
Pharmaceutics
ISSN: 1999-4923
Titre abrégé: Pharmaceutics
Pays: Switzerland
ID NLM: 101534003
Informations de publication
Date de publication:
02 Nov 2023
02 Nov 2023
Historique:
received:
11
10
2023
revised:
25
10
2023
accepted:
27
10
2023
medline:
25
11
2023
pubmed:
25
11
2023
entrez:
25
11
2023
Statut:
epublish
Résumé
The freeze-drying of biopharmaceuticals is a common strategy to extend their shelf-life and facilitate the distribution of therapeutics. The drying phase is the most demanding one in terms of energy consumption and determines the overall process time. Our previous work showed how the loading configuration can impact freezing. This paper focuses on primary drying by comparing the thermal behaviour of vials loaded in direct contact with the shelf or nested in a rack system. The overall heat transfer coefficient from the apparatus to the product was evaluated at different chamber pressures (5-30 Pa) and shelf temperatures (from -10 °C to +30 °C), and in the case of various vial positions (central, semi-border, and border vials). Because of the suspended configuration, the heat transfer coefficient was less affected by chamber pressure in vials nested in a rack system. The two loading configurations displayed comparable heat transfer efficiency below 10 Pa. For higher chamber pressure, the heat transfer coefficients of nested vials were lower than those of vials in direct contact with the shelf. Nevertheless, the rack system was beneficial for reducing the inter-vial variability as it promoted higher uniformity in the heat transfer coefficients of central vials. Eventually, thermal image analyses highlighted limited temperature differences between the vials and the rack system.
Identifiants
pubmed: 38004549
pii: pharmaceutics15112570
doi: 10.3390/pharmaceutics15112570
pmc: PMC10674193
pii:
doi:
Types de publication
Journal Article
Langues
eng
Subventions
Organisme : Stevanato Group
ID : no grant number
Références
J Pharm Sci. 2017 Mar;106(3):770-778
pubmed: 27939928
Int J Pharm. 2013 Jul 15;451(1-2):23-33
pubmed: 23624086
Pharmaceutics. 2023 Mar 07;15(3):
pubmed: 36986722
J Pharm Sci. 2012 Nov;101(11):4025-31
pubmed: 22893524
AAPS PharmSciTech. 2011 Sep;12(3):854-61
pubmed: 21710335
J Pharm Sci. 2021 Mar;110(3):1219-1226
pubmed: 33069707
AAPS PharmSciTech. 2011 Mar;12(1):372-8
pubmed: 21347620
Pharmaceutics. 2023 Feb 14;15(2):
pubmed: 36839958
AAPS PharmSciTech. 2021 Jan 27;22(2):57
pubmed: 33502633
Int J Pharm. 2022 Nov 25;628:122233
pubmed: 36183914
J Pharm Sci. 2014 Sep;103(9):2673-2695
pubmed: 24916125
J Pharm Sci. 2019 Jan;108(1):391-398
pubmed: 30077699
J Pharm Sci. 1984 Sep;73(9):1224-37
pubmed: 6491939
J Pharm Sci. 2021 Mar;110(3):1323-1336
pubmed: 33275993
J Pharm Sci. 2011 Jan;100(1):311-24
pubmed: 20575053
J Pharm Sci. 2023 Dec;112(12):3088-3098
pubmed: 37399888
Drug Discov Today Technol. 2008 Autumn;5(2-3):e81-8
pubmed: 24981095
PDA J Pharm Sci Technol. 2005 Mar-Apr;59(2):138-53
pubmed: 15971546
Pharm Res. 2004 Feb;21(2):191-200
pubmed: 15032301
J Pharm Sci. 2011 Nov;100(11):4922-33
pubmed: 21702051
Pharm Res. 2022 Oct;39(10):2597-2606
pubmed: 35925479